Nexvet Biopharma plc Ordinary Shares
NVET
NVET was delisted on the 28th of July, 2017.
17 hedge funds and large institutions have $50.7M invested in Nexvet Biopharma plc Ordinary Shares in 2015 Q1 according to their latest regulatory filings, with 17 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$23.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$12.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.28M |
| 4 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$6.7M |
| 5 |
Jennison Associates
New York
|
+$4.39M |
Top Sellers
NVET Hedge Fund Activity: Q1 2015 in Review
17 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Nexvet Biopharma plc Ordinary Shares (NVET) for Q1 2015, worth a combined $50.7M.
Buyers outnumbered sellers: 17 funds opened new NVET positions and 0 closed out — a net gain of 17 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $23.7M.
- 17 institutional investors held Nexvet Biopharma plc Ordinary Shares (NVET) as of Q1 2015, up from 0 in Q4 2014.
- Funds reported $50.7M of Nexvet Biopharma plc Ordinary Shares stock for Q1 2015.
- 17 funds opened new Nexvet Biopharma plc Ordinary Shares positions in Q1 2015 and 0 closed out, a net change of +17 holders.
- The largest Nexvet Biopharma plc Ordinary Shares buyer in Q1 2015 was Farallon Capital Management, an estimated $23.7M added.
Based on aggregated 13F filings for Q1 2015.